Definium Therapeutics (NASDAQ:DFTX) Insider Matthew Wiley Sells 2,867 Shares of Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) insider Matthew Wiley sold 2,867 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the transaction, the insider directly owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This trade represents a 1.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Definium Therapeutics Price Performance

Shares of DFTX stock opened at $44.95 on Friday. The business has a fifty day simple moving average of $24.59 and a 200 day simple moving average of $19.36. The company has a market cap of $4.48 billion, a P/E ratio of -18.05 and a beta of 2.37. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics, Inc. has a twelve month low of $6.40 and a twelve month high of $47.01.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). On average, sell-side analysts forecast that Definium Therapeutics, Inc. will post -2.29 EPS for the current fiscal year.

Trending Headlines about Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
• Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
• Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
• Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
• Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

Hedge Funds Weigh In On Definium Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada boosted its holdings in Definium Therapeutics by 10.4% in the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after acquiring an additional 6,148 shares during the last quarter. Creative Planning raised its holdings in Definium Therapeutics by 2.6% during the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after purchasing an additional 1,655 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Definium Therapeutics by 5.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock worth $315,000 after purchasing an additional 2,342 shares during the period. Rhumbline Advisers lifted its position in shares of Definium Therapeutics by 6.3% in the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock worth $748,000 after purchasing an additional 6,839 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares during the last quarter. 27.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Piper Sandler reiterated an “overweight” rating and set a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a research report on Friday, May 8th. Canaccord Genuity Group set a $60.00 target price on shares of Definium Therapeutics in a research note on Monday. Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a research note on Monday. HC Wainwright boosted their price objective on Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Robert W. Baird upped their target price on Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $47.08.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.